Healing monoclonal antibodies (mAbs) represent a milestone in pharmacological development. as foreign [13, 14]. Nevertheless, further characterization of CIC-dependent adverse reactions in preclinical species is usually of high interest to the pharmaceutical industry [15]. A more profound understanding of the underlying mechanisms would help to minimize the risks in animal models and the likelihood of… Continue reading Healing monoclonal antibodies (mAbs) represent a milestone in pharmacological development. as